Does AMIVANTAMAB Cause Malignant neoplasm progression? 12 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Malignant neoplasm progression have been filed in association with AMIVANTAMAB (Rybrevant). This represents 1.6% of all adverse event reports for AMIVANTAMAB.
12
Reports of Malignant neoplasm progression with AMIVANTAMAB
1.6%
of all AMIVANTAMAB reports
8
Deaths
1
Hospitalizations
How Dangerous Is Malignant neoplasm progression From AMIVANTAMAB?
Of the 12 reports, 8 (66.7%) resulted in death, 1 (8.3%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for AMIVANTAMAB. However, 12 reports have been filed with the FAERS database.
What Other Side Effects Does AMIVANTAMAB Cause?
Infusion related reaction (62)
Rash (61)
Pulmonary embolism (41)
Dermatitis acneiform (34)
Thrombocytopenia (33)
Paronychia (29)
Diarrhoea (25)
Pneumonitis (24)
Dyspnoea (23)
Nausea (23)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which AMIVANTAMAB Alternatives Have Lower Malignant neoplasm progression Risk?
AMIVANTAMAB vs AMIVANTAMAB-VMJW
AMIVANTAMAB vs AMLODIPINE
AMIVANTAMAB vs AMLODIPINE BESILATE
AMIVANTAMAB vs AMLODIPINE\ATORVASTATIN
AMIVANTAMAB vs AMLODIPINE\BENAZEPRIL